Impact of regulatory safety warnings on the use of antidepressants among children and adolescents in finland

Journal of Child and Adolescent Psychopharmacology

Volumn 20, Issue 2, 2010, Pages 145-150

  Foulon, Veerle ^a   Svala, Anni ^b   Koskinen, Hanna ^c   Chen, Timothy F ^d   Saastamoinen, Leena K ^c   Bell, J Simon ^b,d,e  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b UNIVERSITY OF HELSINKI   (Finland)

^c SOCIAL INSURANCE INSTITUTION   (Finland)

^d UNIVERSITY OF SYDNEY   (Australia)

^e UNIVERSITY OF EASTERN FINLAND   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; ANTIDEPRESSANT AGENT; CITALOPRAM; CLOMIPRAMINE; DOXEPIN; DULOXETINE; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; MIANSERIN; MILNACIPRAN; MIRTAZAPINE; MOCLOBEMIDE; MONOAMINE OXIDASE INHIBITOR; NORTRIPTYLINE; PAROXETINE; REBOXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRAZODONE; TRIMIPRAMINE; VENLAFAXINE;

ADOLESCENT; ARTICLE; CHILD; DRUG MONITORING; DRUG SAFETY; DRUG USE; FINLAND; HUMAN; MEDICAL INFORMATION; PREVALENCE; REIMBURSEMENT;

ADOLESCENT; ANTIDEPRESSIVE AGENTS; CHILD; CHILD, PRESCHOOL; DRUG AND NARCOTIC CONTROL; DRUG LABELING; DRUG UTILIZATION; FEMALE; FINLAND; HUMANS; INCIDENCE; MALE; PHYSICIAN'S PRACTICE PATTERNS; PREVALENCE;

EID: 77951686513     PISSN: 10445463     EISSN: None     Source Type: Journal    
DOI: 10.1089/cap.2009.0040     Document Type: Article

References (35)

1. Aalto-Setälä V, Kanerva R, Bell JS: Drug cost development of cita-lopram and fluoxetine following the introduction of generic substitution in Finland. Int J Pharm Med 21:363-368, 2007.
2. Anderson RN, Smith BL: Deaths: Leading causes for 2002. Natl Vital Stat Rep 53:1-89, 2005.
3. Autti-Rämö I, Seppänen J, Raitasalo R, Martikainen JE, Sourander A: Increase in use of psychotropics among adolescents and young adults since the beginning of the 21st century [in Finnish]. Suom Laakaril 64:477-482, 2009.
4. Bennett K, Teeling M, Feely J: Overprescribing of antidepressants to children: Pharmacoepidemiological study in primary care. BMJ 331:1451-1452, 2005.
5. Bhatia SK, Rezac AJ, Vitiello B, Sitorius MA, Buehler BA, Kra-tochvil CJ: Antidepressant prescribing practices for the treatment of children and adolescents. J Child Adolesc Psychopharmacol 18:70-80, 2008.
6. Bonati M, Clavenna A: The epidemiology of psychotropic drug use in children and adolescents. Int Rev Psychiatry 17:181-188, 2005. (Pubitemid 40827295)
7. Bramness JG, Engeland A, Furu K: Use of antidepressants among children and adolescents\did the warnings lead to fewer prescriptions? [in Norwegian]. Tidsskr Nor Laegeforen 127:2653-2655, 2007.
8. Dean AJ, Hendy A, McGuire T: Antidepressants in children and adolescents\changes in utilisation after safety warnings. Pharma-coepidemiol Drug Saf 16:1048-1053, 2007.
9. Delate T, Gelenberg AJ, Simmons VA, Motheral BR: Trends in the use of antidepressants in a national sample of commercially insured pediatric patients, 1998 to 2002. Psychiatr Serv 55:387-391, 2004.
10. Fegert JM, Kolch M, Zito JM, Glaeske G, Janhsen K: Antidepressant use in children and adolescents in Germany. J Child Adolesc Psychopharmacol 16:197-206, 2006.
11. Gardarsdottir H, Heerdink ER, Egberts AC: Potential bias in phar-macoepidemiological studies due to the length of the drug free period: A study on antidepressant drug use in adults in the Netherlands. Pharmacoepidemiol Drug Saf 15:338-343, 2006.
12. Gibbons RD, Brown CH, Hur K, Marcus SM, Bhaumik DK, Erkens JA, Herings RMC, Mann JJ: Early evidence on the effects of regulators' suicidality warnings on SSRI prescriptions and suicide in children and adolescents. Am J Psychiatry 164:1356-1363, 2007.
13. Käypä hoito. Current Care Guidelines: Depression [in Finnish]. Helsinki: Finnish Medical Society Duodecim; 2009.
14. Kurdyak PA, Juurlink DN, Mamadani MM: The effect of antide-pressant warnings on prescribing trends in Ontario, Canada. Am J Public Health 97:750-754, 2007.
15. Kurian BT, Ray WA, Arbogast PG, Fuchs C, Dudley JA, Cooper WO: Effect of regulatory warnings on antidepressant prescribing for children and adolescents. Arch Pediatr Adolesc Med 161:690-696, 2007.
16. Libby AM, Brent DA, Morrato EH, Orton HD, Allen R, Valuck RJ: Decline in treatment of pediatric depression after FDA advisory on risk of suicidality with SSRIs. Am J Psychiatry 164:884-891, 2007.
17. Ma J, Lee K, Stafford R: Depression treatment during outpatient visits by U.S. children and adolescents.J Adolesc Health 37:434-442, 2005.
18. Moreno C, Arango C, Parellada M, Shaffer D, Bird H: Anti-depressants in child and adolescent depression: Where are the bugs? Acta Psychiatr Scand 115:184-195, 2007.
19. Murray ML, de Vries CS, Wong ICK: A drug utilisation study of antidepressants in children and adolescents using the General Practice Research Database. Arch Dis Child 89:1098-1102, 2004.
20. Murray ML, Thompson M, Santosh PJ, Wong ICK: Effects of the Committee on Safety of Medicines advice on antidepressant prescribing to children and adolescents in the UK. Drug Safety 28:1151-1157, 2005.
21. National Agency for Medicines & The Social Insurance Institution of Finland. Helsinki: Finnish Statistics on Medicines, 2006.
22. Nemeroff CB, Kalali A, Keller MB, Charney DS, Lenderts SE, Cascade EF, Stephenson H, Schatzberg AF: Impact of publicity concerning pediatric suicidality data on physician practice patterns in the United States. Arch Gen Psychiatry 64:466-472, 2007.
23. Reseland S, Bray I, Gunnell D: Relationship between antidepressant sales and secular trends in suicide rates in the Nordic countries. Br J Psychiatry 188:354-358, 2006.
24. Ryan ND: Treatment of depression in children and adolescents. Lancet 366:933-940, 2005.
25. Sevilla-Dedieu C, Kovess-Masfety V: Psychotropic medication use in children and adolescents: A study from France. J Child Adolesc Psychopharmacol 18:281-289, 2008.
26. Sourander A, Ellilä H, Välimäki M, Aronen ET: Psychopharmaco-logical treatment of child and adolescent psychiatric inpatients in Finland. J Child Adolesc Psychopharmacol 12:147-155, 2002. (Pubitemid 34779028)
27. Usala T, Clavenna A, Zuddas A, Bonati M: Randomised controlled trials of selective serotonin re-uptake inhibitors in treating depression in children and adolescents: A systematic review and meta-analysis. Eur Neuropsychopharmacol 18:62-73, 2008.
28. Vitiello B: An international perspective on pediatric psychopharma-cology. Int Rev Psychiatry 20:121-126, 2008.
29. Volkers AC, Heerdink ER, van Dijk L: Antidepressant use and off-label prescribing in children and adolescents in Dutch general practice (2001-2005). Pharmacoepidemiol Drug Saf 16:1054-1062, 2007.
30. Wagner KD, Robb AS, Findling RL, Jin J, Gutierrez MM, Heydorn WE: A randomized, placebo-controlled trial of citalopram for the treatment of major depression in children and adolescents. Am J Psychiatry 161:1079-1083, 2004.
31. Wagner KD, Jonas J, Findling RL, Ventura D, Saikali K: A double-blind, randomized, placebo controlled trial of escitalopram in the treatment of pediatric depression. J Am Acad Child Adolesc Psychiatry 45:280-288, 2006
32. WHO Collaborating Centre for Drug Statistics Methodology: Anatomical Therapeutic Chemical Classification System. WHO Collaborating Centre for Drug Statistics Methodology. Oslo: Norwegian Institute of Public Health, 2006.
33. Zito JM, Safer DJ, DosReis S, Gardner JF, Soeken K, Boles M, Lynch F: Rising prevalence of antidepressants among US youths. Pediatrics 109:721-727, 2002.
34. Zito JM, Tobi H, de Jong-van den Berg LTW, Fegert JM, Safer DJ, Janhsen K, Hansen DG, Gardner JF, Glaeske G: Antidepressant prevalence for youths: A multi-national comparison. Pharmacoe-pidemiol Drug Saf 15:793-798, 2006.
35. Zito J, Safer D, Berg L, Janhsen K, Fegert J, Gardner J, Glaeske G, Valluri S: A three-country comparison of psychotropic medication prevalence in youth. Child Adolesc Psychiatry Ment Health 2:26, 2008.